Application Nr Approved Date Route Status External Links
NDA020796 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications Entacapone Tablets Are Indicated As An Adjunct To Levodopa And Carbidopa To Treat End-Of-Dose “wearing-Off” In Patients With Parkinson’s Disease (See Clinical Pharmacology, Clinical Studies). Entacapone Tablets’ Effectiveness Has Not Been Systematically Evaluated In Patients With Parkinson’s Disease Who Do Not Experience End-Of-Dose “wearing-Off”.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Entacapone ENTACAPONE ZINC35342787

Comments